20:50 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Arca reports Phase IIb data for Gencaro in heart failure patients

Arca biopharma Inc. (NASDAQ:ABIO) reported top-line data from the Phase IIb GENETIC-AF trial in 267 heart failure patients with reduced left ventricular ejection fraction (LVEF) showing that Gencaro bucindolol hydrochloride led to a "similar treatment...
02:20 , Feb 24, 2017 |  BC Week In Review  |  Clinical News

AEOL 10150: Ph I started

Aeolus began an open-label, dose-escalation, U.S. Phase I trial to evaluate single doses of subcutaneous AEOL 10150 in up to 12 healthy volunteers. The company is developing AEOL 10150 for the indication under a contract...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Financial News

Aeolus completes private placement of common stock and warrants

Aeolus Pharmaceuticals Inc. (OTCQB:AOLS), Mission Viejo, Calif.   Business: Neurology, Pulmonary, Autoimmune   Date completed: 2015-12-14   Type: Private placement of common stock and warrants   Raised: $2.2 million   Shares: 10.2 million   Price: $0.22   Shares after offering: 146.1 million...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Financial News

Aeolus completes private placement of convertible preferred stock and warrants

Aeolus Pharmaceuticals Inc. (OTCQB:AOLS), Mission Viejo, Calif.   Business: Neurology, Pulmonary, Autoimmune   Date completed: 2015-12-14   Type: Private placement of convertible preferred stock and warrants   Raised: $4.5 million   Shares outstanding prior: 135.9 million   Placement agent: Laidlaw   Investor:...
07:00 , Oct 29, 2015 |  BC Innovations  |  Emerging Company Profile

Rebuilding the barrier

Leuvas Therapeutics Inc., Mountain View, Calif. Approved therapies for epilepsy control seizures by suppressing firing, but the drugs are ineffective in about one third of patients, produce psychological side effects, and don't address the underlying cause....
07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

Aeolus preclinical data

In a rat model of epilepsy, AEOL 10150 improved spatial memory following administration of pilocarpine. AEOL 10150 also significantly reduced nerve cell death, inhibited oxidative stress caused by seizures and reduced deficits in mitochondrial respiration....
07:00 , May 21, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: DNA-directed DNA polymerase γ (POLG)

Other INDICATION: Progeria In vitro studies suggest scavenging reactive oxygen species (ROS) and peroxynitrites could help treat Cockayne syndrome, a pediatric genetic disorder characterized by accelerated aging and growth defects. Fibroblasts from Cockayne syndrome patients had lower...
07:00 , Apr 27, 2015 |  BC Week In Review  |  Clinical News

Gencaro bucindolol regulatory update

FDA granted Fast Track designation to Arca’s Gencaro bucindolol to prevent atrial fibrillation/atrial flutter in patients with reduced left ventricular ejection fraction (LVEF). The non-selective beta blocker and mild vasodilator is in Phase IIb/III testing...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Aeolus preclinical data

In non-human primates, AEOL 10150 given for 60 days increased survival to 50% from 25% at 180 days after radiation exposure to the lungs. Aeolus said the data will be included in a pre-emergency use...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

Gencaro bucindolol: Phase IIb/III started

Arca began the double-blind, placebo-controlled, U.S. Phase IIb/III GENETIC-AF trial to compare 6.25, 12.5, 25, 50 and 100 mg oral Gencaro twice daily vs. 25, 50, 100 and 200 mg oral Toprol-XL metoprolol succinate...